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In clinical practice, assessment of expiratory nitric oxide (FENO) may reveal eosi-
nophilic airway inflammation in asthmatic and other pulmonary diseases. Cur-
rently, measuring of FENO is standardized to exhaled flow level of 50 ml s
1,
since the expiratory flow rate affects the FENO results. To enable the comparison
of FENO measured with different expiratory flows, we firstly aimed to establish a
conversion model to estimate FENO at the standard flow level, and secondly, vali-
date it in five external populations. FENO measurements were obtained from 30
volunteers (mixed adult population) at the following multiple expiratory flow
rates: 50, 30, 100 and 300 ml s1, after different mouthwash settings, and a con-
version model was developed. We tested the conversion model in five popula-
tions: healthy adults, healthy children, and patients with COPD, asthma and
alveolitis. FENO conversions in the mixed adult population, in healthy adults and
in children, showed the lowest deviation between estimated F^ENO from
100 ml s1 and measured FENO at 50 mL s
1: 028 ppb, 044 ppb and
027 ppb, respectively. In patients with COPD, asthma and alveolitis, the deviation
was 116 ppb, 168 ppb and 147 ppb, respectively. We proposed a valid
model to convert FENO in healthy or mixed populations, as well as in subjects
with obstructive pulmonary diseases and found it suitable for converting FENO
measured with different expiratory flows to the standard flow in large epidemio-
logical data, but not on individual level. In conclusion, a model to convert FENO
from different flows to the standard flow was established and validated.
Introduction
Chronic bronchial inflammation of the respiratory mucosa can
lead to bronchial hyperreactivity and airway obstruction. Clini-
cians often employ fractional exhaled nitric oxide (FENO) to
evaluate bronchial eosinophilic inflammation (NICE, 2017).
FENO values are flow-dependent, and an expiratory flow rate of
50 ml s1 mirrors the bronchial nitric oxide (NO) production
and not the NO with peripheral origin (Tsoukias & George,
1998; H€ogman et al., 2000). For this reason, FENO measurement
is currently standardized at the expiratory flow rate of
50 ml s1 (ATS/ERS, 2005, Horvath et al., 2017). Prior to the
standardization, FENO was acquired in Northern Europe with
expiratory flow rates of 50-300 ml s1 (H€ogman et al., 1997;
Ekroos et al., 2002; Rouhos et al., 2008) and a previous guide-
line endorsed the use of flow rates between 167 and
250 ml s1 (Kharitonov et al., 1997). Many pioneers in FENO
investigation adopted a flow rate of 100 ml s1 (Kharitonov &
Barnes, 2001). Unfortunately, data measured at different flow
levels have been difficult to compare, since FENO values are
affected by the flow rate used and represent NO from anatomi-
cally different lung parts. Therefore, a conversion method to
interpolate FENO values to equivalent FENO values at diverse flows
was needed. Since the lowering effect of mouthwashes on FENO
values is well documented (Lassmann-Klee et al., 2018a,b), the
conversion method should address also the mouthwashes. The
aim of this study was to establish a method for converting FENO,
measured at different expiratory flow levels, to the standard
FENO measured at 50 ml s
1 and validate this method. Further
on, we aimed to determine the need of considering the mouth-
washes in the conversion method.
Glossary
FENO, Fractional exhaled nitric oxide
F^ENO, Estimated fractional exhaled nitric oxide
_V, Expiratory flow rate
NO, Nitric Oxide
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Methods
Data acquisition
We recruited 30 healthy or asthmatic adults as volunteers
(henceforth referred as ‘mixed adult population’) to develop a
conversion method. We have previously described this popu-
lation (Lassmann-Klee et al., 2018b). The volunteers were
adult patients (n = 9) or healthcare workers (n = 21). The
patients invited were previously referred for FENO assessment
to the Laboratory of Clinical Physiology or to the Skin and
Allergy Hospital at the Helsinki University Central Hospital
area. The healthcare employees were included in the study
without exclusions. The patients enrolled had respiratory
symptoms or a chronic respiratory disease, including asthma
(n = 4), eosinophilic bronchitis (n = 1), building-related res-
piratory symptoms (n = 3) and Sj€ogren’s syndrome (n = 1).
Spirometric data (n = 25) were analysed, and none of the par-
ticipants had actual bronchodilator reversibility (Pellegrino
et al., 2005).
FENO measurements were performed at the Finnish Institute
of Occupational Health and at the Skin and Allergy Hospital
with CLD 88 sp chemiluminescence NO analysers and
EXHALIZER’s D devices using SPIROWARE software (Eco
Medics AG, Switzerland). The devices were calibrated in com-
pliance with the producer’s specifications: use of certified span
gas (AGA Gas BV, Amsterdam, Netherlands) and a zero-air fil-
tering system (DENOX 88 unit). Additionally, a calibration
syringe (Hans Rudolph Inc., USA) was used to calibrate the
ultrasonic flow sensor. We complied with all advices from the
ATS/ERS statement (ATS/ERS, 2005).
We performed FENO measurements in our mixed adult pop-
ulation (n = 30) from September 2016 until May 2017, and
the tests for each volunteer were scheduled on 2 consecutive
days. All the 30 volunteers followed a mouthwash protocol
with tap water and carbonated water. Detailed description of
the mouthwashes’ protocol is available in our recent study
(Lassmann-Klee et al., 2018b). Briefly, the FENO measurements
were performed after a mouthwash with 100 ml of tap water
at each flow level. After 15 min, all measurements were
repeated after a mouthwash with 100 ml of carbonated water
at each flow level. The mouthwashes’ effect, duration and
chemical composition are well documented (Lassmann-Klee
et al., 2018a,b).
Secondly, we selected 10 healthcare workers from the
aforementioned volunteers to perform an additional measure-
ment phase. The selection criterion was inclusion only of
those employed at the Skin and Allergy Hospital. In the third
appointments, the 10 healthcare workers performed the mea-
surements without a mouthwash.
FENO was acquired from all participants at the following
multiple expiratory flow rates: 50, 30, 100 and 300 ml s1.
At least two measurements of FENO were obtained at each flow
level. The values were accepted, if its variation was less than
2 ppb.
Validation
For validating our conversion method, 5 different datasets of
previously published articles acquired at the Tampere Univer-
sity Hospital were available. They contained multiple-flow
data from 69 healthy adults (Lehtim€aki et al., 2010a,b), 66
healthy children (Sepponen et al., 2008), 74 steroid-naive
adults with COPD (Lehtim€aki et al., 2010a), 40 steroid-naive
adults with asthma (Lehtim€aki et al., 2001) and 17 subjects
with untreated alveolitis (Lehtim€aki et al., 2001). The valida-
tion process is explained in the statistical section.
This study followed the ethical principles of the declaration
of Helsinki (World Medical Association Declaration of
Helsinki, 2013) and received approval from an ethical
committee (99/13/03/00/15). All participants signed an
informed consent.
Statistics
Modelling the conversion method
Analyses were performed using RSTUDIO version 11383
frontend to the R statistics language (R Core Team, 2018).
We agreed on a significance level of a = 005 as significant.
We calculated the arithmetic mean from individual FENO val-
ues obtained at each flow level. The mean values were plotted
against the expiratory flow rate _V in a double logarithmic
scale, and we performed a non-linear regression. We obtained
a slope and intercept and analysed the regression line to
develop our conversion model. To further refine the model,
we acquired a non-linear least squares estimation of the non-
linear model parameters. This model was used to estimate
F^ENO values from FENO values measured at different flow rates.
Validation
To test the validity of our model, we converted FENO values
measured at 30, 100 and 300 ml s1 to estimated F^ENO values
for a standard flow rate of 50 ml s1. Afterwards, we com-
pared the estimated F^ENO values to the actual FENO measured at
50 ml s1. To assess the agreement between estimated F^ENO
and measured FENO, we performed an analysis (see below)
according to Bland & Altman (2010). Further on, the correla-
tion coefficient rho was obtained with Spearman’s formula to
investigate linearity.
To validate our conversion model in different external popu-
lations, we compared the estimated F^ENO converted from
100 ml s1 with FENO measured at 50 or 40 ml s
1. For this
external validation, a method described by Bland & Altman
(2010) was employed. Accordingly, we obtained the individual
differences of FENO, the mean of differences (bias) and the 196
standard deviations of the mean (95% limits of agreement).
Additionally, we performed a linear regression analysis
(glm) between FENO values measured at 50 ml s
1 after the
tap water and carbonated water mouthwashes, to obtain a
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relation between the mouthwashes and to provide an addi-
tional equation to convert measurements with these two
mouthwashes to the standard flow level (50 ml s1).
When necessary, raw data were examined for outliers using
the absolute deviation around the median (3 deviations as
threshold). If cases were omitted, the conversion was repeated
and the differences and level of agreements adjusted (Leys
et al., 2013).
Results
Conversion model
We plotted the mean FENO values against the expiratory flow
rate _V and performed a non-linear regression. Acquiring non-
linear least squares parameter estimates resulted in a slope of
08416 SE(03192) for carbonated water, a slope of 084
SE(02989) for tap water and a slope of 083111 SE
(005424) in the absence of a mouthwash. In the latter case,
the equation model can be further defined as:
F^ENO ¼ k  _V083111 ð1Þ
Plotting our model with Eq. using measured FENO and _V,
as well as calculated values for k, resulted in Fig. 1.
The linear regression of FENO at 50 ml s
1 after a tap water
mouthwash in relation to carbonated water resulted in a slope
coefficient of 1055 ppb and intercept of 0354 ppb (P<0001).
When employing the different estimating slopes for the
F^ENO conversions with tap water and carbonated water mouth-
washes, the mean estimated F^ENO for the carbonated water
mouthwash was ca. 45% lower than the mean estimated
F^ENO for tap water at all flow levels (unadjusted).
Validation results in mixed adult population
Using Eq. 1, we calculated the values for F^ENO (flow level
50 ml s1) interpolated from data obtained at 100 ml s1.
Applying the (Bland & Altman, 2010) method resulted in
mean (SD) differences between the estimated F^ENO (flow level
50 ml s1) and the measured FENO (flow level 50 ml s
1) of
-045(244) ppb, upper 95% limit of agreement of 434 ppb
and lower 95% limit of agreement of 523 ppb. The mea-
sured FENO and the estimated F^ENO had a good correlation
(Spearman’s q = 087; P<00001).
We also estimated F^ENO (50 ml s
1) from values measured
at all flow levels and mouthwash settings. All differences with
the (Bland & Altman, 2010) method showed a good agree-
ment, and the total unadjusted mean of the absolute deviation
of F^ENO from FENO was 072 ppb. All estimated values were
highly correlated with corresponding measured values.
Table 1 summarizes these results. Figure 2 exemplifies the
unadjusted mean differences of F^ENO and FENO after applying
Eq. 1 (conversion with carbonated water mouthwash from
flow of 100 ml s1). After adjusting measured FENO by
removing outliers and performing a new estimation, a better
agreement was found between estimated F^ENO and measured
FENO, and total mean of the absolute deviations of F^ENO from
FENO was 066 ppb. The adjusted results after controlling for
outliers can be also found in Table 1.
Validation results in external populations
With the same approach, we converted FENO data obtained at
100 ml s1 (Lauri Lehtim€aki et al., 2001; Sepponen et al.,
2008; Lehtim€aki et al., 2010a,b) to estimated F^ENO (flow level
50 or 40 ml s1) without a mouthwash (Eq. ). The mean dif-
ference between estimated F^ENO and measured FENO was low-
est (027 ppb) in the healthy children group, followed by the
healthy adult group (044 ppb), as shown in Fig. 3. The
mean difference illustrated in Fig. 2 of steroid-naive adults
with asthma was 168 ppb. In Fig. 4, the mean difference
shown is 116 ppb in steroid-naive adults with COPD, and
147 in the untreated alveolitis population. The healthy groups
had narrow limits of agreement, in contrast to the groups
with diseases. Table 2 synthesizes these results. Additionally,
Fig. 5 demonstrates the distribution of the differences in all
populations. Table 3 contains the correlation between the
measured and estimated FENO values and provides information
concerning the linearity between the values.
Discussion
Conversion model
We found that using a non-linear regression yielded a simple
model to convert FENO values measured at different flows to
estimated F^ENO at 50 ml s
1. To prove the feasibility of the
equation, we compared estimated F^ENO levels at the standard
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Figure 1 FENO as a function of expiratory flow (without mouth-
wash), n = 10. Curve shows the equationF^ENO ¼ k  _V083111.
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flow (50 ml s1) from all flow levels (30, 100 and
300 ml s1), with FENO acquired at 50 ml s
1 and found a
good mean agreement between the estimated and measured
values. The limits of agreement between estimated F^ENO and
FENO were reasonable.
Validation
Assessment of the conversion in external datasets, including
data of a wide range of pulmonary diseases and multiple-flow
FENO values, confirmed these previous findings. The conver-
sion model developed showed the lowest deviation in FENO
conversions in healthy children, healthy adults and in our
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Figure 3 Bland–Altman plot with mean of FENO measured at
50 ml s1 and estimated F^ENO from 100 ml s
1 in healthy children
(grey dots, n = 66) and in healthy adults (black dots, n = 69), plot-
ted against the differences in FENO. In healthy children: mean differ-
ences (grey dotted line), 196 standard deviations (grey dot-slashed
line). In healthy adults: mean differences (black solid line), 196 stan-
dard deviation (black slashed line).
Table 1 Bland–Altman statistics in our mixed healthy and asthmatic adult population (n = 30) and in healthcare workers (n = 10) with mean,
biasa, levels of agreement and standard deviation (SD) of the differences between estimated F^ENO from different flow levels and mouthwashes, and
measured FENO at 50 ml s
1 (tap water: 2727 ppb; carbonated water: 2551 ppb; no mouthwash: 2205)
Mean estimated F^ENO (ppb) at
50 ml s1 from flow level and
mouthwash Biasa
Adjusted values
Level of agreement Level of agreement
Lower Upper SD biasa Lower Upper SD rho b
30 ml s1; tap 2524 203 1117 710 466 123 544 30 215 096 3
100 ml s1; tap 2699 028 742 686 364 011 367 344 181 098 3
300 ml s1; tap 2627 100 1902 1701 919 074 579 727 333 095 2
30 ml s1; carbonated 2423 128 492 236 186 150 490 190 173 099 3
100 ml s1; carbonated 2565 013 428 455 225 008 332 316 165 099 4
300 ml s1; carbonated 2507 044 1332 1243 657 099 469 667 290 095 4
30 ml s1; no mouthwash 2164 041 589 506 279 041 589 506 279 084 0
100 ml s1; no mouthwash 2160 045 523 434 244 045 523 434 244 087 0
300 ml s1; no mouthwash 2162 043 567 482 268 043 567 482 268 082 0
Raw data and adjusted values for outliers. Rho according to Spearman’s test.
aaverage of the differences between estimated F^ENO and measured FENO.
bNumber of observations excluded with the adjustment.
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Figure 2 Bland–Altman plot with mean of measured FENO and esti-
mated F^ENO from 100 ml s
1 in asthmatics (grey dots, n = 40) and
our mixed adult population (black dots, n = 30), plotted against the
differences in FENO. In asthmatics: mean differences (grey dotted line),
196 standard deviations (grey dot-slashed line). In mixed adult popu-
lation: mean differences (black solid line), 196 standard deviation
(black slashed line). In asthmatics FENO measured at 40 ml s
1. In
mixed adult population FENO measured at 50 ml s
1 after carbonated
water mouthwash.
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mixed asthmatic and healthy adult population. In the steroid-
naive asthmatic, alveolitis and COPD populations, the average
differences in FENO were moderate with moderate limits of
agreement. In the population with COPD, some single individ-
uals showed a considerable deviation.
We acknowledge the limitation of this conversion proce-
dure, that is being only an approximation that may result in a
considerable deviation between estimated and physiological
values especially at extreme FENO and/or flow levels, as
observed in conversions from low flow (30 ml s1) or high
expiratory flow (300 ml s1) levels. Nevertheless, this equa-
tion is useful when comparing the FENO medians of large pop-
ulation data measured at different flow levels, being very
reliable on the group level, although not on individual level.
The conversion model developed suits best FENO conversions
in healthy adults, healthy children and in a mixed adult popu-
lation, showing the lowest deviation. This novel conversion
model mimics physiological expiratory NO values propor-
tional to expiratory flows. Similar FENO and expiratory flow
curves were previously described by other researchers
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Figure 4 Bland–Altman plot with mean of measured FENO and esti-
mated F^ENO from 100 ml s
1 in COPD patients (grey dots, n = 72)
and patients with alveolitis (black dots, n = 17), plotted against the
differences in FENO. In COPD patients: mean differences (grey dotted
line), 196 standard deviations (grey dot-slashed line). In patients
with alveolitis: mean differences (black solid line), 196 standard
deviation (black slashed line). In patients with alveolitis FENO mea-
sured at 40 ml s1. In COPD patients FENO measured at 50 ml s
1.
Table 2 Bland–Altman statistics with biasa, levels of agreement and
standard deviation (SD) of the differences between estimated F^ENO
from 100 ml s1 (Eq. 1) and measured FENO at 50 or 40 ml s
1
Population Biasa
Level of
agreement
SDLower Upper
Mixed healthy and asthmatic
adults
028 742 686 364
Healthy adults 044 387 298 174
Asthmatic 168 1136 799 494
Healthy children 027 194 248 113
COPD 116 1146 913 525
Alveolitis 147 828 1122 498
aaverage of the differences between estimated F^ENO and measured
FENO§.
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Figure 5 Density plot with mean differences between FENO measured
at 50 or 40 ml s1 and estimated F^ENO from 100 ml s
1, and the
density of the individual mean differences in all study groups. [Colour
figure can be viewed at wileyonlinelibrary.com]
Table 3 Spearman’s correlation between estimated F^ENO from
100 ml s1 and measured FENO at 50 ml s
1, with 95% CI and P val-
ues
Population Correlation
95% CI
PLower Upper
Mixed healthy and
asthmatic adults
099 098 099 <0001
Healthy adults 097 095 098 <0001
Asthmatic 099 098 099 <0001
Healthy children 097 095 098 <0001
COPD 098 096 098 <0001
Alveolitis 087 068 095 <0001
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(Tsoukias & George, 1998; Silkoff et al., 2000), but this model
uses a simplified approach in estimating F^ENO and makes no
claim in predicting flow-independent parameters.
Since the conversion model developed derives from healthy
and asthmatic adults without alveolar diseases, the slope
reflects only very low amounts of alveolar nitric oxide concen-
tration (CANO). We previously determined CANO in our mixed
healthy and asthmatic group and all results were under
23 ppb (Lassmann-Klee et al., 2018b). Logically, the slope
and the estimating equation would change, if switching the
participants with subjects with high alveolar NO. The conver-
sion method produces errors in those subjects in whom the
relation between alveolar and bronchial NO production is very
different from the group mean, as the slope between FENO
and _V is very different in these subjects. Therefore, the model
may result in erroneous estimates when applied to subjects
with known high alveolar nitric oxide concentrations. Empha-
sis should be made, not to employ the model without discre-
tion in this type of subjects. The elimination of outliers could
represent a limitation of our study, although we did not
observe drastic changes when comparing the bias between
crude and adjusted data. This statistical adjustment merely nar-
rowed the limits of agreement and served the purpose of
demonstrating how the model estimates FENO values stemming
from adjusted datasets.
Further on, regression estimates were obtained for FENO
values between the mouthwashes, in order to facilitate an
interpolation between FENO values measured at 50 ml s
1
after carbonated, and tap water, and vice versa. Our estimat-
ing equation provides different slopes for both mouth-
washes. The mean estimated F^ENO values were ca. 4% lower
for the carbonated water mouthwash than the tap water
mouthwash. This approximate difference between these
mouthwashes was previously confirmed (Lassmann-Klee
et al., 2018a,b). The conversion model succeeds also in con-
sidering the mouthwashes.
In conclusion, we developed an equation for converting
FENO values obtained with different flow levels to FENO with
standard flow (50 ml s1), taking also into account the even-
tual mouthwash. We proposed a novel model to convert FENO
in healthy populations, as well in subjects with obstructive
pulmonary diseases. We conclude that the model is reliable in
converting FENO in large epidemiological data and might be
applied in small scale populations with pulmonary diseases,
but not on individual level.
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